A New Prodrug Strategy Could Make Diabetes Peptide Drugs Last Longer and Need Fewer Injections | Research

The takeaway

A PEG-based prodrug system using cleavable peptide linkers protected GLP-1 and amylin analogs from degradation and provided stable drug levels for over 24 hours, potentially enabling once-monthly dosing.

<2% degradation after 24 hours
Taspoglutide within the PEG-prodrug remained almost completely intact after 24 hours in serum, demonstrating that the PEG conjugation effectively shielded the peptide from proteolytic breakdown.

What the researchers found

The PEG-prodrug system used protease-cleavable peptide linkers (LVPR, LDPR, and LVPRLVPR) to release therapeutic peptides at controlled rates. Taspoglutide release could be tuned over more than one order of magnitude, providing stable serum levels from approximately 0.08 to 3 μmol/L for about 20 hours.

Amylin and pramlintide levels were maintained at approximately 20 nmol/L and remained stable for at least 24 hours. Critically, the PEG attachment protected the peptides from degradation: after 24 hours in serum, less than 2% of taspoglutide within the prodrug was degraded. The researchers suggest that combining this technology with other formulation strategies could enable once-monthly administration.

Why it matters

Current GLP-1 and amylin-based drugs require daily or weekly injections, which can reduce patient adherence. A prodrug technology that protects these peptides from degradation while providing controlled release could dramatically extend dosing intervals. Less frequent injections would improve quality of life for millions of diabetes and obesity patients.

How the study worked

Researchers designed PEG-peptide prodrugs using three different protease-cleavable linker sequences to connect PEG to the therapeutic peptides taspoglutide (GLP-1 analog), amylin, and pramlintide (amylin analog). They measured release kinetics and stability in mouse serum, tracking both the rate of active peptide release and the degree of peptide degradation over time.

What this study cannot tell us

The study was conducted in mouse serum in vitro, not in living animals or humans. In vivo pharmacokinetics, efficacy, and safety have not been tested. PEG conjugation can sometimes trigger immune responses (anti-PEG antibodies) with repeated dosing, which was not addressed. The actual achievability of once-monthly dosing is speculative and would require extensive further development and formulation optimization.

How to read the evidence

This is an early-stage preclinical study conducted entirely in vitro using mouse serum. While the results are promising and well-characterized, no in vivo or clinical data exist to validate the approach in living systems.

When this study was published

Published in 2018, this study describes a prodrug platform technology. Since then, the field of long-acting peptide drugs has continued to advance, but the PEG-prodrug concept remains relevant for extending peptide half-lives.

The bigger picture

The push to create longer-acting peptide therapeutics is a major theme in diabetes and obesity drug development. While weekly GLP-1 drugs like semaglutide have been commercially successful, once-monthly or less frequent dosing remains a goal. This PEG-prodrug approach offers a modular platform that could be applied to various therapeutic peptides beyond just GLP-1 and amylin, potentially transforming how peptide drugs are formulated and delivered.

Questions still open

Will this PEG-prodrug system maintain its controlled release profile in vivo, where additional clearance mechanisms are at play?
Could anti-PEG antibodies develop with repeated dosing and reduce effectiveness over time?
Can this platform be combined with subcutaneous depot formulations to truly achieve once-monthly administration?

Common questions

What is a prodrug and how does it help peptide medications?

A prodrug is an inactive form of a drug that converts to the active form inside the body. In this case, the therapeutic peptide is attached to PEG through a special linker that slowly breaks down, gradually releasing the active drug. This protects the peptide from being destroyed by the body's enzymes and provides a steady, long-lasting drug supply.

Could this technology lead to once-monthly diabetes injections?

The researchers suggest it is possible. Their system kept peptide drugs stable and active for over 24 hours in lab tests. By combining this approach with other formulation strategies (like slow-release depot injections), monthly dosing could potentially be achieved, though this has not yet been tested in animals or humans.

Read the original research

PEGylated prodrugs of antidiabetic peptides amylin and GLP-1.

Journal of controlled release : official journal of the Controlled Release Society, 292, 58-66

View on PubMed ↗Publisher’s paper ↗

Citation

Böttger, Roland; Knappe, Daniel; Hoffmann, Ralf. (2018). PEGylated prodrugs of antidiabetic peptides amylin and GLP-1.. Journal of controlled release : official journal of the Controlled Release Society, 292, 58-66. https://doi.org/10.1016/j.jconrel.2018.05.001